Regular ArticleClustered CD20 Induced Apoptosis: Src-Family Kinase, the Proximal Regulator of Tyrosine Phosphorylation, Calcium Influx, and Caspase 3-Dependent Apoptosis☆,☆☆,★
References (37)
- et al.
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
Blood
(1998) - et al.
CD20: A regulator of cell-cycle progression of B lymphocytes
Immunol. Today
(1994) - et al.
Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment
J. Biol. Chem.
(1998) - et al.
Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20
J. Biol. Chem.
(1995) - et al.
The association between CD20 and Src-family tyrosine kinases requires an additional factor
Mol. Immunol.
(1998) - et al.
Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation
J. Biol. Chem.
(1996) - et al.
A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V
J. Immunol. Methods
(1995) - et al.
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
Blood
(1994) Inhibitory signaling by B cell Fc gamma RIIb
Curr. Opin. Immunol.
(1998)- et al.
Intracellular phosphotyrosine induction by major histocompatibility complex class II requires co-aggregation with membrane rafts
J. Biol. Chem.
(1999)
HLA class II molecule signal transduction leads to either apoptosis or activation via two different pathways
Cell Immunol.
Activation of a calcium-permeable cation channel CD20 expressed in Balb/c 3T3 cells by insulin-like growth factor-I
J. Biol. Chem.
Role for tyrosine phosphorylation and Lyn tyrosine kinase in fas receptor-mediated apoptosis in eosinophils
Blood
Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes
Blood
Application of a fluorometric assay to detect caspase activity in thymus tissue undergoing apoptosis in vivo
J. Immunol. Methods
Monoclonal antibody-based therapies for hematologic malignancies
J. Clin. Oncol.
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
J. Clin. Oncol.
Growth inhibition of CD20-positive B lymphoma cell lines by IDEC–C2B8 anti-CD20 monoclonal antibody
Jpn. J. Cancer Res.
Cited by (202)
Multi-targeted immunotherapeutics to treat B cell malignancies
2023, Journal of Controlled ReleaseClinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma
2023, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2Anti-CD20 antibody treatment for diffuse large B cell lymphoma: Genetic alterations and signaling pathways
2023, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases
2023, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease
2022, Pharmacology and Therapeutics
- ☆
Abbreviations used: BAPTA-AM, acetoxymethyl ester of 1,2-bis (2-aminophenoxy) ethane-N,N,N′,N′-tetracetic acid; BSA, bovine serum albumin; DEVD, peptide composed of aspartic acid–glutamic acid–valine–aspartic acid; DMSO, dimethyl sulfoxide; EGTA, ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetracetic acid; FcR, Fc receptor; FITC, fluorescein isothiocyanate; GAM, goat anti-mouse IgG; ITAM, immunoreceptor tyrosine-based activation motif; NHL, non-Hodgkin's lymphoma; PLC, phospholipase C; PI, propidium iodide; PTK, protein tyrosine kinase.
- ☆☆
This work was supported by NIH Grants AI41447 and CA64268. Dr. Coggeshall is a scholar of the Leukemia Society of America, and Dr. Hofmeister is supported by a Fellowship from the Lymphoma Research Foundation of America, Inc.
- ★
Communicated by Alvin, Mauer, M.D., 03/16/00
- f1
Correspondence and reprint requests to: Dr. K. M. Coggeshall, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK. 73104. Fax: (405) 271-8568. E-mail: [email protected].